JAZZJazz Pharmaceuticals plc
Is it safe?
Nothing alarming, nothing pristine: insiders quiet, comfortable debt (A), and typical volatility.
Insiders were net sellers (-$24.9M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -52% · now 17% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can JAZZ take a bad year?
Jazz Pharmaceuticals plc carries $2.73B of net debt at 2.18× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 2.18×
Net debt / EBITDA · 86.7× a year ago · the load is coming down
- Debt / equity
- 0.91×
Debt / equity
- Annualised volatility
- 36%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $4.35B
- Cash and short-term investments
- $1.62B
- Net debt
- $2.73B
- EBITDA, trailing twelve months
- $1.25B
- Operating profit, trailing twelve months
- $897M
- Debt / equity
- 0.91×
- Total debt / EBITDA
- 3.47×
- Annualised volatilitytwo years of daily moves
- 36%
- Worst drawdown on file
- −52%
- Below its 52-week high
- 17%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.